- Home
- MYND vs NTRB Comparison
MYND vs NTRB Comparison
Compare MYND & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYND | NTRB |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 72.6M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MYND | NTRB |
|---|---|---|
| Price | $0.34 | $7.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 98.2K |
| Earning Date | 05-27-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $2.80 |
| 52 Week High | $1.01 | $9.00 |
Technical Indicators
Market Signals| Indicator | MYND | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 65.16 |
| Support Level | $0.30 | $3.68 |
| Resistance Level | $0.51 | N/A |
| Average True Range (ATR) | 0.05 | 0.97 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 28.59 | 69.53 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.